Bernstein downgrades Alnylam to Market Perform, cuts price target to $199

Bernstein analyst Jeffrey Walch downgraded Alnylam Pharmaceuticals to Market Perform from Outperform, citing concerns over the design of the TRITON-CM Phase 3 trial for nucresiran. Walch cut his price target to $199 from $376 on reduced probability of success and lower sales projections.

Detected & updated continuously · Source: Nebula